Quarterly report [Sections 13 or 15(d)]

Condensed Statements of Operations (Unaudited)

v3.25.1
Condensed Statements of Operations (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Income Statement [Abstract]    
Revenues
Operating Expenses:    
Research and development 1,099,000 777,000
Selling, general and administrative (including $3,000 and $102,000 from stock compensation for the three months ended March 31, 2025 and 2024, respectively) 833,000 2,314,000
Loss from Operations (1,932,000) (3,091,000)
Other Income (Expense)    
Interest income 32,000 142,000
Change in fair value of warrant liability 126,000 658,000
Gain on settlement of vendor payable 998,000
Other 27,000
Unrealized gain on short-term investments (2,000)
Total Other Income, Net 1,156,000 825,000
Net Loss $ (776,000) $ (2,266,000)
Net Loss Per Share - Basic $ (0.33) $ (1.64)
Net Loss Per Share - Diluted $ (0.33) $ (1.64)
Weighted average common shares outstanding - basic 2,345,087 1,380,633
Weighted average common shares outstanding - diluted 2,345,087 1,380,633